文献速递新发突发、热带与寄生虫病

圭亚那地区恶性疟原虫哌喹耐药对疟疾治疗效果的影响:一项描述性流行病学研究

Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in The Guianas: a descriptive epidemiological study.
PubMed 文献 · Lancet Infect Dis · 2023-10-16

发现86株分离株中40株(47%)体外对哌喹耐药,耐药表型与pfCRTC350R及pfpm2/pfpm3扩增相关,这些标记也与治疗失败相关(6例中3例失败)。苏里南和圭亚那耐药标记流行率高,作者呼吁该地区慎用双氢青蒿素-哌喹。

要点

  • 法属圭亚那86株恶性疟原虫野外分离株中40株(47%)体外对哌喹耐药。
  • 哌喹耐药表型与pfCRTC350R及pfpm2/pfpm3扩增相关(Dunn检验 p<0.001)。
  • 苏里南35株中19株(83%)、圭亚那791株中579株(73%)携带哌喹耐药标记。

核心结论

  • 圭亚那地区寄生虫种群中哌喹耐药标记高流行及相关治疗失败风险,呼吁该地区慎用双氢青蒿素-哌喹。
  • 应更多关注不同大陆遗传背景不同的寄生虫种群间基因型到表型映射的潜在差异。

研究设计与样本

  • 对法属圭亚那当代分离株进行pfCRT基因分型(n=845)及pfpm2、pfpm3拷贝数检测(n=231),体外哌喹存活试验表型分析(n=86),基因组研究(n=50)。
  • 另对来自五个亚马逊国家及该区域外一个国家的样本进行基因分型(n=1440)。

主要发现

  • 86株野外分离株中40株(47%,95%CI 35.9–57.1)体外对哌喹耐药;这些表型与pfCRTC350R及pfpm2、pfpm3扩增更相关(Dunn检验 p<0.001)。
  • 上述标记也与双氢青蒿素-哌喹治疗失败相关(6例中3例失败,50%)。
  • 苏里南35株分离株中19株(83%)、圭亚那791株中579株(73%)哌喹耐药标记高流行。
  • pfCRTC350R突变在pfpm2和pfpm3扩增之前出现,时间顺序与东南亚不同,且不伴青蒿素部分耐药,提示这些遗传标记间存在地理上独特的 epistatic 关系。

关键数值与推荐

  • 86株中40株(47%,95%CI 35.9–57.1)体外哌喹耐药。
  • 苏里南35株中19株(83%)、圭亚那791株中579株(73%)携带哌喹耐药标记。
  • 6例接受双氢青蒿素-哌喹治疗的患者中3例(50%)治疗失败。

临床怎么用

  • 作者结论指出,圭亚那地区哌喹耐药标记高流行及相关治疗失败风险,呼吁该地区慎用双氢青蒿素-哌喹。
  • 作者建议应更多关注不同大陆遗传背景不同的寄生虫种群间基因型到表型映射的潜在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium falciparum is an apicomplexan parasite responsible for lethal cases of malaria. According to WHO recommendations, P falciparum cases are treated with artemisinin-based combination therapy including dihydroartemisinin-piperaquine. However, the emergence of resistant parasites against dihydroartemisinin-piperaquine was reported in southeast Asia in 2008 and, a few years later, suspected in South America. METHODS: To characterise resistance emergence, a treatment efficacy study was performed on the reported patients infected with P falciparum and treated with dihydroartemisinin-piperaquine in French Guiana (n=6, 2016-18). Contemporary isolates collected in French Guiana were genotyped for P falciparum chloroquine resistance transporter (pfCRT; n=845) and pfpm2 and pfpm3 copy number (n=231), phenotyped using the in vitro piperaquine survival assay (n=86), and analysed through genomic studies (n=50). Additional samples from five Amazonian countries and one outside the region were genotyped (n=1440). FINDINGS: In field isolates, 40 (47%) of 86 (95% CI 35·9-57·1) were resistant to piperaquine in vitro; these phenotypes were more associated with pfCRTC350R (ie, Cys350Arg) and pfpm2 and pfpm3 amplifications (Dunn test, p<0·001). Those markers were also associated with dihydroartemisinin-piperaquine treatment failure (n=3 [50%] of 6). A high prevalence of piperaquine resistance markers was observed in Suriname in 19 (83%) of 35 isolates and in Guyana in 579 (73%) of 791 isolates. The pfCRTC350R mutation emerged before pfpm2 and pfpm3 amplification in a temporal sequence different from southeast Asia, and in the absence of artemisinin partial resistance, suggesting a geographically distinctive epistatic relationship between these genetic markers. INTERPRETATION: The high prevalence of piperaquine resistance markers in parasite populations of the Guianas, and the risk of associated therapeutic failures calls for caution on dihydroartemisinin-piperaquine use in the region. Furthermore, greater attention should be given to potential differences in genotype to phenotype mapping across genetically distinct parasite populations from different continents. FUNDING: Pan American Health Organization and WHO, French Ministry for Research, European Commission, Santé publique France, Agence Nationale de la Recherche, Fundação de Amparo à Pesquisa do Estado do Amazonas, Ministry of Health of Brazil, Oswaldo Cruz Foundation, and National Institutes of Health. TRANSLATIONS: For the French and Portuguese translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Florimond C, de Laval F, Early AM, et al. Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in The Guianas: a descriptive epidemiological study. Lancet Infect Dis. 2023. PMID: 37858325. doi:10.1016/S1473-3099(23)00502-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。